Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
Zhang, Chiyuan Amy
Rice, Meghan A
Brooks, James D
Gnanapragasam, Vincent J
Br J Cancer
Springer Science and Business Media LLC
MetadataShow full item record
Liu, S., Shen, M., Hsu, E., Zhang, C. A., Garcia-Marques, F., Nolley, R., Koul, K., et al. (2021). Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.. Br J Cancer, 124 (5), 896-900. https://doi.org/10.1038/s41416-020-01200-0
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.
Biomarkers, Tumor, Carrier Proteins, Cytokines, Follow-Up Studies, Humans, Male, Prognosis, Prostatectomy, Prostatic Neoplasms, Survival Rate
External DOI: https://doi.org/10.1038/s41416-020-01200-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331823
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com